Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Bayer's Q3 earnings rose on strong Crop Science and Pharma sales, with CEO Bill Anderson confident in meeting the company&#...
Bayer (OTC:BAYRY) raises FY2025 sales outlook from $52.154 billion-$54.422 billion to $53.784 billion-$56.123 billion.
Bayer (OTC:BAYRY) reported quarterly earnings of $0.17 per share. This is a 142.86 percent increase over earnings of $0.07 per ...
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer p...
Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid f...
Bayer (OTC:BAYRY) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.24 by 45.83 pe...
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety c...
Bayer Q1 profit declined to $1.45 billion, but earnings and sales topped estimates as pharma growth offset crop science headwin...
